Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337916 | 1.00 | — | — | |
| SCHEMBL15967967 | 1.00 | TSHR (0.30) | TSHR | |
| SCHEMBL21179486 | 1.00 | TSHR (0.30) | TSHR | |
| SCHEMBL97177 | 0.93 | — | — | |
| SCHEMBL2141485 | 0.86 | TSHR (0.30) | TSHR | |
| SCHEMBL10990883 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL4986121 | 0.86 | TSHR (0.30) | TSHR | |
| Bromide SCHEMBL10984057 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL10842729 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL4986134 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114751909-A | Preparation method of Ribociclib intermediate | 杭州福斯特药业有限公司 | 2022-07-15 | — | — | CN | claimed |
| CN-112876589-B | Organic polymer catalyst, preparation method thereof and application thereof in preparation of polyether polyol | 万华化学集团股份有限公司 | 2022-04-22 | — | — | CN | claimed |
| CN-112876589-A | Organic polymer catalyst, preparation method thereof and application thereof in preparation of polyether polyol | 万华化学集团股份有限公司 | 2021-06-01 | — | — | CN | claimed |
| CN-119630672-A | Camptothecin derivative and conjugate thereof, and preparation method and medical application thereof | 一线医药（杭州）有限公司 | 2025-03-14 | — | — | CN | disclosed |
| CN-118475557-A | Compound, curable resin composition, cured product, diffraction optical element, and augmented reality glasses | 富士胶片株式会社 | 2024-08-09 | — | — | CN | disclosed |
| CN-110799190-B | Heterocyclic compounds | 卡都瑞恩医药有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2023246914-A1 | HETEROCYCLIC SUBSTITUTED PYRIMIDOPYRAN COMPOUND AND USE THEREOF | 南京明德新药研发有限公司 | 2023-12-28 | — | — | WO | disclosed |
| CN-114751909-B | Preparation method of rebaudinib intermediate | 杭州福斯特药业有限公司 | 2023-10-27 | — | — | CN | disclosed |
| CN-116568677-A | piperidin-1-yl-N-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of MTAP deficiency and/or MTA accumulating cancers | 探戈医药股份有限公司 | 2023-08-08 | — | — | CN | disclosed |
| CN-116490017-A | Organic electroluminescent element and electronic equipment thereof | 宁波卢米蓝新材料有限公司 | 2023-07-25 | — | — | CN | disclosed |
| CN-114751909-A | Preparation method of Ribociclib intermediate | 杭州福斯特药业有限公司 | 2022-07-15 | — | — | CN | disclosed |
| WO-2010017105-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-11 | — | — | WO | disclosed |
| WO-2010013794-A1 | SPIROAMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029616-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-04 | — | — | US | disclosed |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20090209755-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-08-20 | — | — | US | disclosed |
| US-7538123-B2 | Indole derivative having piperidine ring | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-05-26 | — | — | US | disclosed |
| US-20070219179-A1 | Indole Derivative Having Piperidine Ring | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-09-20 | — | — | US | disclosed |
| EP-1757599-A1 | INDOLE DERIVATIVES HAVING PIPERIDINE RINGS | Eisai R&D Management Co., Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-20050256103-A1 | Indole derivative having piperidine ring | EISAI CO., LTD. | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209755-A1 | FUSED AMINODIHYDROTHIAZINE DERIVATIVES | BACE1, APP, BACE2 | TSHR 3087/4885 |
| US-20070219179-A1 | Indole Derivative Having Piperidine Ring | HTR5A, HTR2C, HTR1A | TSHR 365/4885 |
| US-20100029616-A1 | UROTENSIN II RECEPTOR ANTAGONISTS | UTS2R, PLAUR, BDKRB2 | TSHR 409/4885 |
| US-20050256103-A1 | Indole derivative having piperidine ring | HTR5A, HTR2C, HTR1A | TSHR 428/4885 |
| US-20090270369-A1 | BICYCLOAMINE DERIVATIVES | SCN1B, KCNJ2, KCNH2 | TSHR 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.